A Study to Evaluate the DDI of DBPR108 With Metformin,Glibenclamide,Valsartan, or Simvastatin in Healthy Subjects
Status:
Completed
Trial end date:
2021-07-09
Target enrollment:
Participant gender:
Summary
This is a four-part, single-center, open-label, single-sequence crossover phase I clinical
study to characterize the Drug-Drug Interaction (DDI) potential of DBPR108 at steady-state
with Metformin hydrochloride, Glibenclamide, Valsartan, or Simvastatin in Healthy Subjects.
This study also aims to evaluate the safety and tolerability of DBPR108 in the presence of
Metformin hydrochloride, Glibenclamide, Valsartan, or Simvastatin.